[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 145
1. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Of the 37 adenocarcinomas, all were negative for PSA and PSAP (0/37; 0%).
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


2. Cekanova M, Lee SH, Donnell RL, Sukhthankar M, Eling TE, Fischer SM, Baek SJ: Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev Res (Phila); 2009 May;2(5):450-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethane-induced pulmonary adenomas and adenocarcinomas were observed in control mice; however, only pulmonary adenomas were observed in NAG-1(Tg+/FVB) mice.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2005 Feb;67(2):356-64 [15509713.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2425-32 [15308587.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18636-42 [15757899.001]
  • [Cites] Circulation. 2005 May 17;111(19):2494-502 [15867183.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):35-45 [15949588.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1763-75 [16314486.001]
  • [Cites] Prog Lipid Res. 2006 Jan;45(1):1-16 [16337272.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1352-61 [16731769.001]
  • [Cites] Apoptosis. 2006 Jul;11(7):1131-8 [16699947.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):566-74 [16741990.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1553-60 [17101328.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1164-73 [17315157.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6863-71 [17638897.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Nov;323(2):746-56 [17715378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Exp Cell Res. 2008 Mar 10;314(5):1105-14 [18062963.001]
  • [Cites] Mol Carcinog. 2008 Mar;47(3):197-208 [18058799.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):809-19 [18360708.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1174-86 [18375740.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):175-82 [10623665.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] Trends Biochem Sci. 2000 Jun;25(6):257-60 [10838561.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):20127-35 [10777512.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):901-8 [11259636.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):425-34 [11895857.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1388-98 [11984525.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5845-53 [12475986.001]
  • [Cites] Mol Pharmacol. 2003 Mar;63(3):557-64 [12606762.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6883-92 [14662774.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s [15217972.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1517-24 [15033900.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9 [9326641.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):49617-23 [15377673.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 4;328(1):63-9 [15670751.001]
  • (PMID = 19401523.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108975-03; United States / NCI NIH HHS / CA / R01 CA108975; United States / NCI NIH HHS / CA / CA108975-03; United States / NCI NIH HHS / CA / R01 CA 108975; United States / NCI NIH HHS / CA / R01 CA108975-04; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / CA108975-01A2; United States / NCI NIH HHS / CA / R01 CA108975-02; United States / NCI NIH HHS / CA / R01 CA108975-01A2; United States / NCI NIH HHS / CA / CA108975-02; United States / NCI NIH HHS / CA / CA108975-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Growth Differentiation Factor 15; 3IN71E75Z5 / Urethane; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS118668; NLM/ PMC2697576
  •  go-up   go-down


3. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rosulek A, Li H, Yang K, Fan K, Lipkin M, Bronson RT, Jelicks L, Kunkel TA, Kucherlapati R, Edelmann W: An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology; 2010 Mar;138(3):993-1002.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resulting adenomas and adenocarcinomas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene.

  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.Cg-Msh2<tm2.1Rak>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Nat Genet. 2000 Jun;25(2):139-40 [10835623.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Nov;29(3):229-39 [10992298.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5755-63 [11126362.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5193-201 [11431359.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7369-74 [11606363.001]
  • [Cites] Genome Res. 2003 Mar;13(3):476-84 [12618378.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):603-14 [12629043.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Mol Carcinog. 2003 Dec;38(4):155-9 [14639654.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):517-22 [14744764.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):261-5 [15139004.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1091-101 [15279797.001]
  • [Cites] Genesis. 2004 Jul;39(3):186-93 [15282745.001]
  • [Cites] Fam Cancer. 2004;3(2):123-7 [15340263.001]
  • [Cites] J Biol Chem. 1991 Feb 25;266(6):3744-51 [1995629.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Nat Genet. 1994 Jun;7(2 Spec No):220-45 [7920646.001]
  • [Cites] Cell. 1995 Jul 28;82(2):321-30 [7628020.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7357-61 [7638196.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):64-70 [7550317.001]
  • [Cites] Genes Dev. 1996 Feb 15;10(4):407-20 [8600025.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5860-5 [8650183.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2922-6 [8674041.001]
  • [Cites] Nucleic Acids Res. 1997 Feb 1;25(3):491-6 [9016586.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3288-93 [9242462.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1678-84 [15578504.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3576-83 [16585182.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9721-30 [17942902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4247-52 [18337503.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15493-8 [18832169.001]
  • [CommentIn] Gastroenterology. 2010 Mar;138(3):820-2 [20102757.001]
  • (PMID = 19931261.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES11040; United States / NCI NIH HHS / CA / U01 CA084301; United States / NCI NIH HHS / CA / CA13330; United States / NCI NIH HHS / CA / CA084301-11; United States / NCI NIH HHS / CA / R01 CA093484; United States / NCI NIH HHS / CA / CA013330-37S49022; United States / NIEHS NIH HHS / ES / Z01 ES065089; United States / NCI NIH HHS / CA / R01 CA076329; United States / Intramural NIH HHS / / Z01 ES065089-12; United States / NCI NIH HHS / CA / R01 CA076329-12; United States / NCI NIH HHS / CA / CA084301; United States / NCI NIH HHS / CA / P30 CA013330-37S49022; United States / NCI NIH HHS / CA / R01 CA093484-08; United States / NCI NIH HHS / CA / U01 CA084301-11; United States / NIEHS NIH HHS / ES / U01 ES011040-06; United States / NIEHS NIH HHS / ES / U01 ES011040; United States / NCI NIH HHS / CA / CA93484; United States / NCI NIH HHS / CA / P30 CA013330; United States / NCI NIH HHS / CA / CA093484-08; United States / NCI NIH HHS / CA / CA76329; United States / NCI NIH HHS / CA / CA076329-12; United States / NIEHS NIH HHS / ES / ES011040-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Microfilament Proteins; 0 / Organoplatinum Compounds; 0 / villin; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.1.3 / Msh2 protein, mouse; EC 3.6.1.3 / MutS Homolog 2 Protein; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS159931; NLM/ PMC2862591
  •  go-up   go-down


Advertisement
4. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • The MCM2 mRNA expression was elevated in the adenoma with villous type, in the conditions of high-grade dysplasia, larger size, sessile morphology and in patients of older ages, but the difference was not significant by REST-XL (P>0.05).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


5. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA: The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology; 2009 May;136(5):1669-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, increased HuR expression and cytoplasmic localization were observed in 76% of adenomas and 94% of adenocarcinomas, and TTP expression was lost in >75% of adenomas and adenocarcinomas.
  • In both adenomas and adenocarcinomas, COX-2 overexpression was associated with increased HuR and decreased TTP (P < .0001); similar associations were observed in colon cancer cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Cell Line, Tumor. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. HeLa Cells. Humans. Immunohistochemistry. RNA, Messenger / analysis. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2157-61 [15781626.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Cancer. 2006;5:37 [16982006.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] J Cell Biochem. 2007 Apr 15;100(6):1477-92 [17133347.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 15;462(2):278-85 [17517366.001]
  • [Cites] Expert Opin Biol Ther. 2007 Oct;7(10):1515-29 [17916044.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1124-36 [18644977.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2030-42, 2042.e1-3 [18824170.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):777-89 [16168373.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):125-31 [10721704.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17827-37 [10751406.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33951-6 [10930401.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1469-74 [11506952.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1657-65 [11733561.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1037-41 [12003384.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):394-9 [12671683.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:52-71 [12795048.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7146-54 [14562043.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7591-4 [14633672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2011-6 [14769925.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32393-400 [15187092.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3448-60 [9628880.001]
  • [CommentIn] Gastroenterology. 2009 May;136(5):1495-8 [19327732.001]
  • (PMID = 19208339.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCI NIH HHS / CA / R01 CA134609
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS488861; NLM/ PMC3742387
  •  go-up   go-down


6. Zhang ZY, Zhao ZR, Jiang L, Li JC, Gao YM, Cui DS, Wang CJ, Schneider J, Wang MW, Sun XF: Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectum. Tumour Biol; 2007;28(2):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectum.
  • OBJECTIVES: It was the aim of this study to investigate Nup88 expression in normal colorectal mucosa, adenoma, adenocarcinoma and lymph node metastasis, as well as the relationship between Nup88 expression and clinicopathological features.
  • METHODS: Nup88 expression was examined by immunohistochemistry in 84 normal mucosa samples, 32 adenomas, 181 primary adenocarcinomas, and 18 lymph node metastases from colorectal tumour patients.
  • The frequency of strong Nup88 expression was increased from normal mucosa or adenoma to primary tumour and lymph node metastasis (p < 0.0001).
  • There was no significant difference in the expression between normal mucosa and adenoma (p = 0.41).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Nuclear Pore Complex Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17264541.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NUP88 protein, human; 0 / Nuclear Pore Complex Proteins
  •  go-up   go-down


7. Oyama T, Yasui Y, Sugie S, Koketsu M, Watanabe K, Tanaka T: Dietary tricin suppresses inflammation-related colon carcinogenesis in male Crj: CD-1 mice. Cancer Prev Res (Phila); 2009 Dec;2(12):1031-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of colonic adenomas and adenocarcinomas was significantly reduced by feeding with 50 and 250 ppm tricin, respectively.
  • Dietary tricin also significantly reduced the proliferation of adenocarcinoma cells as well as the numbers of mitoses/anaphase bridging in adenocarcinoma cells.
  • Our findings that dietary tricin inhibits inflammation-related mouse colon carcinogenesis by suppressing the expression of TNF-alpha in the nonlesional cyrpts and the proliferation of adenocarcinomas suggest a potential use of tricin for clinical trials of colorectal cancer chemoprevention.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenoma / prevention & control. Colonic Neoplasms / prevention & control. Diet. Flavonoids / administration & dosage. Inflammation / prevention & control. Phytotherapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934339.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Flavonoids; 0 / Plant Extracts; 0 / RNA, Messenger; D51JZL38TQ / tricin; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


8. Gyorffy H: [Study of claudins and prognostic factors in some gastrointestinal diseases]. Magy Onkol; 2009 Dec;53(4):377-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I. We explored the changes of CLDN expression in Barrett's esophagus and related adenocarcinoma.
  • Adenocarcinoma showed higher CLDN2 and -3 expression compared with normal and Barrett's epithelia.
  • The similar CLDN expression profile of Barrett's esophagus and adenocarcinoma supports their sequential development.
  • Colorectal adenoma and adenocarcinoma could not be differentiated according to their CLDN profile.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / metabolism. Child. Child, Preschool. Claudin-3. Female. Fluorescent Antibody Technique. Gastrointestinal Stromal Tumors / metabolism. Gene Expression Regulation, Neoplastic. Hemangiosarcoma / metabolism. Humans. Immunohistochemistry. Leiomyosarcoma / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Predictive Value of Tests. Prognosis. RNA, Messenger / metabolism. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071310.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN3 protein, human; 0 / Claudin-3; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


9. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P: Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res; 2006 Dec 1;66(23):11228-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This enzyme is generally not expressed by normal differentiated epithelial colon cells, but has been shown to be up-regulated in human colon adenomas and adenocarcinomas.
  • In this study, we show that LN5 and MMP7 are coexpressed in HT29 cells as well as in HT29 xenograft tumors and human colorectal adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Amino Acid Sequence. Animals. Animals, Newborn. Blotting, Western. Gene Expression Regulation, Neoplastic. HT29 Cells. Humans. Molecular Sequence Data. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145868.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / kalinin; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


10. Gostjeva EV, Thilly WG: Stem cell stages and the origins of colon cancer: a multidisciplinary perspective. Stem Cell Rev; 2005;1(3):243-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of historical age-specific colorectal cancer rates, present day age-specific colonic adenoma prevalence and the few reports of direct measurements of genetic change in human tissues as a function of age in adults have led to a new set of hypotheses about carcinogenesis.
  • In an attempt to overcome this impediment we set reexamined fetal and adult colonic tissue, adenomas, and adenocarcinomas using a novel histological preparation method.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):249-69 [8814991.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Br J Cancer. 1957 Jun;11(2):161-9 [13460138.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Ann N Y Acad Sci. 1975 Aug 22;259:7-16 [54039.001]
  • [Cites] N Engl J Med. 1972 Jun 1;286(22):1178-83 [4623227.001]
  • [Cites] Mutat Res. 1998 May 25;400(1-2):553-78 [9685710.001]
  • [Cites] Adv Cancer Res. 1991;56:161-213 [2028841.001]
  • [Cites] PLoS Biol. 2005 May;3(5):e157 [15839726.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Nucleic Acids Res. 2000 May 1;28(9):E44 [10756211.001]
  • [Cites] Cancer Res. 1964 Oct;24:1544-51 [14234000.001]
  • [Cites] Curr Top Microbiol Immunol. 1968;44:86-99 [4878356.001]
  • [Cites] Br J Cancer. 1954 Mar;8(1):1-12 [13172380.001]
  • [Cites] J Pathol. 1994 Nov;174(3):175-82 [7823250.001]
  • [Cites] Science. 2001 Feb 2;291(5505):843-7 [11225636.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1247-56 [15131784.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):255-9 [12833049.001]
  • [Cites] Br J Cancer. 1953 Mar;7(1):68-72 [13051507.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6 [15247139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3749-53 [8170982.001]
  • [Cites] PCR Methods Appl. 1992 Aug;2(1):14-20 [1490171.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 19;83(12):862-6 [2061946.001]
  • [Cites] Science. 1976 May 7;192(4239):569-72 [130679.001]
  • [Cites] Cytopathology. 2004 Jun;15(3):148-53 [15165271.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nature. 1972 Jan 21;235(5334):137-40 [4110535.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3271-5 [12036944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1972-7 [11842191.001]
  • [Cites] J Theor Biol. 1990 Jul 9;145(1):95-122 [2214810.001]
  • [Cites] Stem Cells Dev. 2004 Dec;13(6):579-84 [15684825.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):508-13 [12147437.001]
  • [Cites] Hum Pathol. 1992 May;23(5):496-503 [1314776.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] J Math Biol. 2004 Nov;49(5):455-67 [15549309.001]
  • (PMID = 17142861.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


11. Iurin AG, Koval'skiĭ GB: [Proliferative activity by expression of antigen Ki-67 in solitary and multiple synchronous epithelial tumors of the colon]. Arkh Patol; 2005 Sep-Oct;67(5):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proliferative activity of sigmoid and rectal mucosa, and that of single and multiple (synchronous) adenomas and adenocarcinomas of the colon has been studied.
  • A significant difference between antigen Ki-67 expression index in normal mucosa, adenomas and adenocarcinomas, and also in single and multiple colorectal cancers has been revealed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Ki-67 Antigen / analysis. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323481.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


12. Manjanatha M, Shelton S, Bishop M, Lyn-Cook L, Aidoo A: Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis; 2006 Oct;27(10):1970-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although DMBA did not induce mammary tumors in the OVX rats, adenoma and adenocarcinoma were detected in the mammary glands of INT rats.

  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Carcinogenesis. 2006 Dec;27(12):2555-64 [17127718.001]
  • (PMID = 16709578.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 0 / Proliferating Cell Nuclear Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6287WC5J2L / daidzein; DH2M523P0H / Genistein; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


13. Ishida M, Hotta M, Kushima R, Tsuruoka S, Ohji M, Okabe H: Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland. Rinsho Byori; 2009 Aug;57(8):746-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • Ductal adenocarcinoma of the lacrimal gland is extremely rare; to our knowledge, only seven de novo cases and one case of ductal adenocarcinoma ex pleomorphic adenoma have been reported in the literature.
  • Here, we report a case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • A 70-year-old Japanese female received the resection of the recurrent lacrimal gland tumor (second surgery), under the clinical diagnosis of recurrent pleomorphic adenoma, fifteen years after the initial surgical resection.
  • The resected tumor was composed of recurrent pleomorphic adenoma and adenocarcinoma.
  • Adenocarcinoma component showed infiltrative papillo-tubular or microcystic growth of carcinoma cells, which had pleomorphic large nuclei with prominent nucleoli and rich eosinophilic cytoplasm.
  • Accordingly, the diagnosis of ductal adenocarcinoma ex pleomorphic adenoma was made.
  • In the previously reported eight cases and the present case of lacrimal ductal adenocarcinomas, recurrence took place in 5 cases and two patients died from multiple metastases.
  • These data suggests that lacrimal ductal adenocarcinoma appears to have a poor prognosis, similar to salivary duct carcinoma, which is one of the most aggressive salivary carcinoma.
  • And further study is needed to clarify the clinicopathological features of the lacrimal ductal adenocarcinoma.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Eye Neoplasms / diagnosis. Eye Neoplasms / pathology. Lacrimal Apparatus. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764409.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


14. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • Our report is the first describing the possible malignant degeneration of a villous adenoma in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


15. Xu B, Zhou ZG, Li Y, Wang L, Yang L, Zhou B, Liu HY, Song JM, Zeng YJ, Wang R, Shen XG, Sun XF: Clinicopathological significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology; 2008;74(3-4):229-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the expression of caspase-8 and -10 in rectal adenoma, adenocarcinoma and the corresponding normal mucosa tissue, and to clarify the relationship between their expression and clinicopathological parameters of rectal cancer.
  • METHODS: The expression of caspase-8 and -10 was determined by real-time RT-PCR and immunohistochemistry in 36 rectal adenomas, 93 rectal cancers and 93 corresponding normal rectal mucosa samples.
  • RESULTS: Compared with normal mucosa, the mRNA expression of caspase-8 was higher in adenomas (p = 0.003), while that of caspase-10 was lower in adenomas (p = 0.035) and cancers (p = 0.001).
  • Immunohistochemical results showed caspase-8 up-regulation in adenomas (p = 0.014), and caspase-10 down-regulation in adenomas (p = 0.034) and cancers (p < 0.001) compared with normal mucosa samples.
  • CONCLUSIONS: Caspase-8 expression was up-regulated in rectal adenomas.
  • Caspase-10 expression was down-regulated in both rectal adenomas and cancers, and was further related to differentiation.
  • [MeSH-major] Adenoma / metabolism. Caspase 10 / metabolism. Caspase 8 / metabolism. Rectal Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18716417.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CASP10 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 10; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


16. Kamei Y, Kito K, Takeuchi T, Imai Y, Murase R, Ueda N, Kobayashi N, Abe Y: Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. Hum Pathol; 2007 Aug;38(8):1273-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 50 cases of colorectal adenomas and adenocarcinomas, the accumulation of hScrib protein was commonly observed in comparison with the adjacent normal epithelia.
  • Like beta-catenin, the intense immunoreactivity of hScrib was often observed in small adenomas, thus, suggesting that hScrib could be involved in an early step of colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509663.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


17. Arévalo F, Arias Stella C, Monge E: [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder]. Rev Esp Enferm Dig; 2007 Dec;99(12):694-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder].
  • [Transliterated title] Inmunoexpresión de p53 y ciclina D1 en adenomas de vesícula biliar.
  • INTRODUCTION: Gallbladder adenomas are infrequent neoplasms whose relation to adenocarcinoma is not well understood.
  • It has been suggested that adenomas and adenocarcinomas follow different molecular pathways.
  • MATERIAL AND METHODS: This is a comparative, cross-sectional study in which we compared p53 and D1 cyclin expression in adenomas and adenocarcinomas of the gallbladder.
  • Expression of p53 occurred in 83.3% of adenocarcinomas and in 16.6% of adenomas (p = 0.003).
  • D1 cyclin was expressed in a similar number of adenomas and adenocarcinomas.
  • CONCLUSION: Our results support the hypothesis that p53 is an important step in the pathogenesis of adenocarcinomas but not of adenomas of the gallbladder.
  • [MeSH-major] Adenoma / metabolism. Cyclin D1 / biosynthesis. Gallbladder Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290692.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


18. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • Colonoscopic biopsies have been taken from the lesion in cancer patients, and colonoscopic polypectomy has been performed for adenomas.
  • No significant difference was detected in the comparison of Ki-67 expression levels between the healthy mucosa and adenomas at the patients with cholecystectomy 43,4 +/- 3,45 (p > 0,05), but more prominent increase was revealed in adenocarcinomas 64,33 +/- 7,67% (p < 0,01).
  • At the patients without cholecystectomy the frequency of revealing p53 in adenomas does not vary, compared with healthy mucosa, however in adenocarcinomas p53 was not revealed at none case.
  • As a contrast, in group of the patients with cholecystectomy the frequency of revealing p53 in adenomas is considerably increased (up to 80%), and even in adenocarcinomas, p53 was revealed in 30,8% of cases.
  • At the patients with a cholecystectomy, the increase of proliferative activity is accompanied by increased apoptosis in adenomas and maintained apoptosis in adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


19. Kang WY, Chen WT, Wu MT, Chai CY: The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis; 2007 Aug;22(8):869-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma.
  • BACKGROUND: The aim of our study was to analyze the expression and possible role of CD66a in colorectal adenoma and adenocarcinoma and the relationship between its expression and pre-operation serum carcinoembryonic antigen (CEA) level and tumor stage in patients with colorectal adenocarcinomas.
  • METHODS: Paraffin-embedded sections from 184 patients including 42 colorectal adenomas with low-grade dysplasia, 43 adenomas with high-grade dysplasia, and 99 adenocarcinomas were collected for this study.
  • RESULTS: The expression of CD66a was found not only in the apical membrane of neoplastic glands but also in secretion within the lumen of the neoplastic glands including adenomas and adenocarcinomas.
  • Expressions of secreted CD66a were of higher level in adenocarcinoma than in adenoma with high-grade dysplasia and adenoma with low-grade dysplasia (p < 0.0001).
  • High expression of secreted CD66a was also associated with tumor stage, invasion, and pre-operation serum CEA level of patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenoma / immunology. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Colorectal Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1236-44 [10728682.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Histochem Cytochem. 1988 Jul;36(7):729-39 [3290331.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1273-84 [11884526.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):313-21 [10419049.001]
  • [Cites] J Cell Biol. 1992 Jul;118(2):457-66 [1378450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10744-8 [7504281.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 23;227(3):775-81 [8886009.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):250-7 [8317550.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):849-56 [8088758.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17894-9 [10749878.001]
  • [Cites] Eur J Biochem. 1993 May 1;213(3):1109-16 [8504806.001]
  • [Cites] J Histochem Cytochem. 1996 Jan;44(1):35-41 [8543780.001]
  • [Cites] J Immunol. 1993 Jun 1;150(11):4978-84 [8496599.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1661-8 [9635845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6959-63 [2457922.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1401-6 [9626043.001]
  • [Cites] Mol Immunol. 1979 Apr;16(4):245-52 [91094.001]
  • [Cites] J Histochem Cytochem. 1997 Jul;45(7):957-63 [9212821.001]
  • (PMID = 17143599.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CTNNB1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


20. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM: Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol; 2005 May;40(5):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The authors used K-ras mice, which develop lung adenomas and adenocarcinomas through somatic activation of the K-ras oncogene.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / pathology. Adenoma / radiography. Animals. Disease Models, Animal. Female. Male. Mice. Mice, Transgenic. Pilot Projects. Radiographic Image Enhancement. Reproducibility of Results. Respiration

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829823.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA80686; United States / NCI NIH HHS / CA / U01 CA84306
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart H, Mori H: Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res; 2007 May 1;67(9):4079-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also treated Apc(Min/+) and wild-type mice with N-methyl-N-nitrosourea (MNU), an alkylating agent that induces adenomas and adenocarcinomas in the stomach.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. T Cell Transcription Factor 1 / metabolism. beta Catenin / metabolism


22. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science; 2009 Mar 27;323(5922):1747-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the offspring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas.


23. Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Kuno T, Kamataki T, Imaida K: 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Rep; 2009 Jul-Aug;2(4):585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
  • Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.
  • In the present study, we examined the inhibitory effects of methoxsalen on the development of lung adenocarcinomas, as well as on adenomas and alveolar hyperplasia.
  • The experiments were terminated 52 weeks after the first methoxsalen treatment, and lung adenomas and adenocarcinomas were analyzed histopathologically.
  • Pretreatment with methoxsalen significantly reduced the incidence of adenocarcinomas from 94.7 to 46.7% (12.5 mg/kg) and 44.4% (1.25 mg/kg), and their tumor multiplicity from 4.68 to 0.87 (12.5 mg/kg) and 0.61 (1.25 mg/kg) tumors/mouse.
  • The tumor multiplicity of adenomas and adenocarcinomas in the methoxsalen-treated groups was significantly reduced from 12.47 to 5.67 (12.5 mg/kg) and 4.28 (1.25 mg/kg) tumors/mouse.
  • Approximately 60% of the adenocarcinomas arose within adenomas.
  • In comparing the methoxsalen + NNK and NNK alone groups, there was no significant difference in the frequency of such compound lesions, indicating that pretreatment with methoxsalen did not suppress the eventual progression of adenomas to adenocarcinomas.
  • These results clearly demonstrate that methoxsalen, a potent human CYP2A6 inhibitor, inhibits not only lung adenoma but also adenocarcinoma development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475870.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


24. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.
  • Among the 8 adenocarcinomas, 5 (62.5%) cases were classified as main duct type, and 3 (37.5%) as combined type.
  • In 7 of the 8 adenocarcinomas, mural nodules were detected within the dilated ducts or cysts of the lesions in which color flow signals were detected.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Cao J, Tang M, Li WL, Xie J, Du H, Tang WB, Wang H, Chen XW, Xiao H, Li Y: Upregulation of activator protein-4 in human colorectal cancer with metastasis. Int J Surg Pathol; 2009 Feb;17(1):16-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression pattern of activator protein-4 in 160 colorectal cancer compared with 32 colorectal adenomas and 32 normal colorectal tissues is demonstrated by tissue microarray-immunohistochemistry and real-time reverse transcriptase-polymerase chain reaction.
  • The activator protein-4 expression in normal colorectal tissue, adenoma, and adenocarcinoma were 4 of 32, 8 of 32, and 78 of 160, respectively.
  • [MeSH-major] Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Lymphatic Metastasis. Transcription Factors / metabolism. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480385.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 0 / enhancer-binding protein AP-4; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


26. López-Köstner F, Fullerton DA, Kronberg U, Soto G, Zúñiga A, Argandoña J, Miranda V, Pinto E: [Screening colonoscopy among first degree relatives of patients with colorectal carcinoma]. Rev Med Chil; 2006 Aug;134(8):997-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the latter, a neoplasm was found in 13 (17%): One adenocarcinoma and 12 adenomas.
  • CONCLUSIONS: Screening colonoscopy is effective to detect adenoma and adenocarcinoma among first degree relatives of patients with colorectal carcinoma, however only 31% of all potential relatives agreed to undergo a colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / standards. Colorectal Neoplasms / diagnosis. Family Health. Mass Screening / psychology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adult. Age Factors. Aged. Attitude. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Prospective Studies. Risk Assessment


27. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


28. National Toxicology Program: Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser; 2008 Jan;(545):1-240
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In F(1)C females, there was a significant positive trend in the incidences of mammary gland adenoma or adenocarcinoma (combined) regardless of whether an unmodified or natural log-transformed dose scale was used in the analysis, and the incidence in the 500 ppm group was significantly greater than that in the control group.
  • In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences.
  • When the natural log-transformed dose scale was used, a marginally significant positive trend occurred in the incidences of adenoma or adenocarcinoma (combined) in F(3)T21 females.
  • There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm.
  • In F(1)C males, a significant positive trend (unmodified dose scale only) occurred in the incidences of combined adenoma or carcinoma of the pancreatic islets.
  • There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms.
  • There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined).

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685716.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phytoestrogens; 0 / Xenobiotics; DH2M523P0H / Genistein
  •  go-up   go-down


29. Wada R: Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation--colorectal Paneth cell metaplasia--colorectal epithelial neoplasia. Digestion; 2009;79 Suppl 1:9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal epithelial neoplasia (CR-EN), both adenoma and adenocarcinoma, may develop from the essential tubules of the colorectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153484.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


30. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


31. Rodrigues S, Rodrigue CM, Attoub S, Fléjou JF, Bruyneel E, Bracke M, Emami S, Gespach C: Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene; 2006 Oct 26;25(50):6628-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
  • To examine the transforming potential of TFF1 in human colon epithelial cells, premalignant PC/AA/C1 adenoma cells (PC) derived from a patient with familial adenomatous polyposis (FAP) were transformed by the TFF1 cDNA and used as a model of the adenoma-carcinoma transition.
  • Accordingly, TFF1 expression is absent in normal human colon crypts but is induced in correlation with Cdc25a and b transcript levels and tumor grade in familial and sporadic colon adenomas and carcinomas.
  • We propose that TFF1 and Cdc25A-B cooperate with other dominant oncogenic pathways to induce the adenoma and adenocarcinoma transitions.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Cell Cycle Proteins / metabolism. Colon / cytology. Colonic Neoplasms / pathology. Intestinal Mucosa / metabolism. Tumor Suppressor Proteins / physiology. cdc25 Phosphatases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715141.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / TFF1 protein, human; 0 / Tumor Suppressor Proteins; EC 3.1.3.16 / CDC25B protein, human; EC 3.1.3.16 / Cdc25a protein, mouse; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


32. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


33. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.
  • Furthermore, only very few data are available on CDX2 expression in normal pituitary gland tissue and/or pituitary adenomas.
  • MATERIAL AND METHODS: We investigated CDX2 expression in 28 normal pituitary glands, 75 pituitary adenomas of varying hormonal activity (including 7 invasive adenomas and 7 atypical adenomas) and 23 craniopharyngiomas (17 adamantinous and 6 papillary) in tissue microarrays.
  • RESULTS: None of the pituitary adenomas, craniopharyngiomas and normal pituitary glands showed expression of CDX2.
  • CONCLUSIONS: There is no evidence for that CDX2 might play a role in tumourigenesis, invasive growth or tumour recurrence of pituitary adenomas or in tumourigenesis of craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


34. Lim SC, Oh SH: The role of CD24 in various human epithelial neoplasias. Pathol Res Pract; 2005;201(7):479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors aimed at evaluating CD24 protein expression in adenoma and adenocarcinoma of the stomach, colon, gallbladder, ovary, and breast to establish a correlation with clinicopathologic data.
  • The present study clearly demonstrates that CD24 is abundantly expressed in adenocarcinoma compared to adenoma of the colon and breast.
  • Intracytoplasmic CD24 expression was found to be highly associated with adenocarcinoma of the colon, gallbladder, and ovary compared to the adenoma group of those organs, and with the positive nodal status compared to the negative nodal status of the colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Membrane Glycoproteins / biosynthesis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164042.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD24; 0 / Biomarkers, Tumor; 0 / CD24 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


35. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, Dietel M, Denkert C: Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol; 2005 Sep 28;11(36):5644-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of PLK1 was investigated by immunohistochemistry (158 cases) and immunoblotting in tissue of colon adenomas and adenocarcinomas.
  • RESULTS: Weak PLK1 expression was observed in normal colon mucosa and adenomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237758.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC4481481
  •  go-up   go-down


36. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


37. Kuno T, Yokohira M, Matsuda Y, Suzuki S, Hashimoto N, Yamakawa K, Saoo K, Imaida K: Lack of modifying potential of 8-methoxypsoralen in the promotion or progression stages of lung carcinogenesis in A/J female mice. Oncol Rep; 2008 Oct;20(4):767-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since it has been reported that CYP2A protein is highly expressed in NNK-induced lung adenomas and adenocarcinomas, potential anticancer properties of 8-MOP in female A/J mice were examined subsequent to initiation.
  • On immunohistochemical analysis, the CYP2A protein was found to be overexpressed in all lung adenomas and adenocarcinomas, with or without 8-MOP.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813816.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CYP2A6 protein, human; 0 / Enzyme Inhibitors; 0 / Nitrosamines; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; EC 1.14.13.- / Cytochrome P-450 CYP2A6; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp2a5 protein, mouse; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


38. Lee JS, Lee KT, Jung JH, Ok SW, Choi SC, Lee KH, Lee JK, Heo JS, Choi SH, Rhee JC: [Factors associated with malignancy in gallbladder polyps without gallbladder stone]. Korean J Gastroenterol; 2008 Aug;52(2):97-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical and radiological features of the polyps were compared between the two groups (neoplastic vs. non-neoplastic) and in the three groups (non-neoplastic vs. adenoma vs. adenocarcinoma).
  • RESULTS: Of 354 patients, non-neoplastic polyps were observed in 229 (64.7%) patents, adenoma in 85 (24.0%) and adenocarcinoma in 40 (11.3%).
  • The mean diameter of non-neoplastic polyp, adenoma, and adenocarcinoma were 11.3+/-2.8 mm, 16.0+/-7.2 mm, and 27.0+/-8.9 mm, respectively.
  • The mean age of patients with non-neoplastic polyp, adenoma, and adenocarcinoma were 44.8+/-11.3, 49.9+/-12.5, and 60.8+/-9.6, respectively.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Odds Ratio. Predictive Value of Tests. ROC Curve

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077501.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


39. Sengottuvelan M, Deeptha K, Nalini N: Resveratrol attenuates 1,2-dimethylhydrazine (DMH) induced glycoconjugate abnormalities during various stages of colon carcinogenesis. Phytother Res; 2009 Aug;23(8):1154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the three dietary regimens of Res, the entire period supplementation significantly (p < 0.01) modulated the levels of glycoconjugates and reduced the incidence of adenoma and adenocarcinoma.

  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • (PMID = 19165800.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Glycoconjugates; 0 / Hexosamines; 0 / Sialic Acids; 0 / Stilbenes; 3713-31-3 / Fucose; IX068S9745 / 1,2-Dimethylhydrazine; Q369O8926L / resveratrol
  •  go-up   go-down


40. Haveri H, Westerholm-Ormio M, Lindfors K, Mäki M, Savilahti E, Andersson LC, Heikinheimo M: Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol; 2008;8:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological tissues examined included samples of chronic and atrophic gastritis as well as adenomas and adenocarcinomas of the colon and rectum.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colonic Neoplasms / genetics. GATA4 Transcription Factor / metabolism. GATA6 Transcription Factor / metabolism. Gastric Mucosa / metabolism. Rectal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1061-72 [9136933.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G297-306 [16603485.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9060-70 [16940177.001]
  • [Cites] Dev Biol. 2002 Jan 1;241(1):34-46 [11784093.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):279-89 [11864602.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 7;1576(1-2):198-202 [12031502.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3136-43 [12130579.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 29;1490(3):324-32 [10684977.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):184-8 [10942535.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3476-83 [10999851.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):699-704 [11029406.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G58-67 [11123198.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1321-57 [11578958.001]
  • [Cites] FEBS Lett. 1997 May 19;408(2):121-3 [9187350.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):G314-24 [9486185.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2901-11 [9566909.001]
  • [Cites] Development. 1998 Dec;125(24):4909-17 [9811575.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Front Biosci. 1999 Mar 15;4:D286-98 [10077541.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(2):71-6 [10190312.001]
  • [Cites] Circ Res. 1999 Apr 2;84(6):647-54 [10189352.001]
  • [Cites] Mol Med. 1999 Jul;5(7):490-501 [10449810.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):952-60 [15541382.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):15-26 [15389642.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):15-24 [15703995.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):368-77 [12527808.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4705-12 [12468531.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):408-12 [15144399.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G899-909 [15178553.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1086-99 [14715527.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10876-80 [8248184.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):361-73 [8045339.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1559-67 [9136834.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • (PMID = 18405344.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA6 Transcription Factor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2323380
  •  go-up   go-down


41. Akatsu T, Aiura K, Shimazu M, Ueda M, Wakabayashi G, Tanabe M, Kawachi S, Kitajima M: Can endoscopic ultrasonography differentiate nonneoplastic from neoplastic gallbladder polyps? Dig Dis Sci; 2006 Feb;51(2):416-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study aimed to clarify the endoscopic ultrasonography (EUS) features of nonneoplastic (cholesterol polyps and adenomyomatosis) and neoplastic (adenoma and adenocarcinoma) gallbladder polyps and to evaluate the effectiveness and limitation of EUS in the differential diagnosis of these lesions.
  • However, three of nine neoplastic lesions (three adenomas and six adenocarcinomas) showed one of these signs due to concomitant cholesterosis (n = 2) or proliferated Rokitansky-Aschoff sinuses (n = 1).
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenoma / diagnostic imaging. Endosonography. Gallbladder Diseases / diagnostic imaging. Gallbladder Neoplasms / diagnostic imaging. Polyps / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1985 Sep;72(9):728-30 [3899247.001]
  • [Cites] J Gastroenterol. 1996 Jun;31(3):470-4 [8726845.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):414-7 [10759734.001]
  • [Cites] Br J Surg. 1992 Mar;79(3):227-9 [1555088.001]
  • [Cites] Am J Gastroenterol. 1988 Jun;83(6):670-4 [3376922.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2226-34 [7127263.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):817 [9121250.001]
  • [Cites] Surgery. 1991 Jan;109(1):107-10 [1984629.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):65-70 [11248179.001]
  • [Cites] Am J Gastroenterol. 1989 Nov;84(11):1386-90 [2683741.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):363-4 [2187556.001]
  • [Cites] World J Surg. 1999 Jul;23 (7):708-12 [10390591.001]
  • [Cites] Gastroenterol Jpn. 1981;16(2):134-40 [7227765.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):630-3 [1595653.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):657-60 [11685029.001]
  • [Cites] Scand J Gastroenterol. 1990 Mar;25(3):281-6 [2320947.001]
  • [Cites] Endoscopy. 2002 Dec;34(12 ):959-65 [12471539.001]
  • [Cites] Arch Surg. 1988 Jan;123(1):26-9 [3276295.001]
  • [Cites] Arch Pathol. 1970 Nov;90(5):423-32 [4319984.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):372-9 [10968853.001]
  • [Cites] Gut. 1996 Dec;39(6):860-2 [9038670.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92 (11):2066-8 [9362194.001]
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):82-5 [8465661.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):61-6 [3942125.001]
  • (PMID = 16534690.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 04;20(2):543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


43. Ma Q, Wang Y, Gao X, Ma Z, Song Z: L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma.
  • PURPOSE: Evidence suggests that the majority of colorectal carcinomas arise from adenomas, and L-arginine suppresses colorectal tumorigenesis.
  • We suppose that L-arginine may inhibit the process of carcinogenesis from colorectal adenoma to adenocarcinoma.
  • EXPERIMENTAL DESIGN: We selected 60 patients with colorectal cancer and 60 patients with colorectal adenoma (CRA) and divided them into four groups of 30 patients each.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / drug therapy. Arginine / therapeutic use. Colorectal Neoplasms / drug therapy. Ornithine Decarboxylase / drug effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094424.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 31C4KY9ESH / Nitric Oxide; 94ZLA3W45F / Arginine; EC 1.14.13.39 / Nitric Oxide Synthase; EC 4.1.1.17 / Ornithine Decarboxylase
  •  go-up   go-down


44. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA: Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila); 2010 Oct;3(10):1303-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PDE5 was found to be overexpressed in colon tumor cell lines as well as in colon adenomas and adenocarcinomas compared with normal colonic mucosa.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Curr Top Med Chem. 2007;7(4):437-54 [17305584.001]
  • [Cites] Mol Cancer Ther. 2009 Dec;8(12):3331-40 [19996273.001]
  • [Cites] Gut. 2006 Mar;55(3):367-73 [16150858.001]
  • [Cites] Adv Exp Med Biol. 1999;470:45-53 [10709673.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3961-8 [11358813.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 [11854387.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):166-74 [11902503.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Adv Pharmacol. 1994;26:87-114 [8038108.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3110-6 [7606732.001]
  • [Cites] J Cell Biochem Suppl. 1995;22:18-23 [8538196.001]
  • [Cites] Physiol Rev. 1995 Oct;75(4):725-48 [7480160.001]
  • [Cites] Biochem Pharmacol. 1996 Jul 26;52(2):237-45 [8694848.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Clin Pharmacokinet. 1997 Jun;32(6):437-59 [9195115.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2909-15 [9230200.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1679-83 [9815550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8 [10377455.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):336-50 [15526282.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Jul 1;172(1):105-13 [15817798.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L196-206 [15792963.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):724-7 [16042585.001]
  • (PMID = 20876730.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128021; United States / NCI NIH HHS / CA / R01 CA148817; United States / NCI NIH HHS / CA / R01 CA155638; United States / NINDS NIH HHS / NS / R21 NS059509; United States / NCI NIH HHS / CA / R01 CA131378; United States / NINDS NIH HHS / NS / R21 NS59509
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / beta Catenin; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 3.1.4.35 / Cyclic Nucleotide Phosphodiesterases, Type 5; H2D2X058MU / Cyclic GMP
  • [Other-IDs] NLM/ NIHMS207934; NLM/ PMC2955813
  •  go-up   go-down


45. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol; 2005 Aug;58(8):833-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
  • AIMS: To examine the relation between p-STAT3 (activated form of STAT3) expression and clinicopathological factors in human colorectal adenocarcinoma and adenoma.
  • METHODS: Immunohistochemical analyses were carried out on tissues from 44 colorectal adenomas and 95 colorectal adenocarcinomas, comprising 18 intramucosal carcinomas and 77 invasive carcinomas.
  • Only eight of the 44 adenomas showed immunopositivity for p-STAT3, resulting in a significant difference between total adenocarcinomas and adenomas (p < 0.001).
  • Among the 95 cases of colorectal adenocarcinoma, p-STAT3 immunoreactivity was significantly correlated with the depth of tumour invasion (p < 0.05), venous invasion (p < 0.05), lymph node metastasis (p < 0.05), and increasing stages of the Dukes' classification (p < 0.01).
  • These findings suggest that p-STAT3 expression is an important factor related to carcinogenesis and/or tumour invasion of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 15;73(8):2076-82 [8156513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2607-11 [10851059.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):230-41 [11281168.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Cancer. 2002 May 1;94(9):2393-400 [12015764.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):209-22 [14603523.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15114-23 [14701810.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1340-5 [3742458.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Cytokine. 1995 Feb;7(2):118-29 [7780031.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):433-42 [9711905.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] J Leukoc Biol. 1998 Nov;64(5):675-80 [9823774.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1267-75 [10081487.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Clin Pathol. 1949 May;2(2):95-8 [16810849.001]
  • (PMID = 16049285.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC1770863
  •  go-up   go-down


46. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A: The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med; 2010;8:112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since inflammation is associated with cancer progression and angiogenesis, we investigated expression of cytokines like IL-6 and other mediators that play a key role in the innate immune system, in particular toll like receptor 4 (TLR4), in the microenvironment of lesions from different stages of colon disease progression, from ulcerative colitis to adenoma and adenocarcinoma to find useful markers.
  • 116 Archival tissue samples from patients with different stages of colorectal disease: 13 cases of ulcerative colitis (UC), 34 tubular or tubulo-villous adenomas (AD), and 53 infiltrating adenocarcinomas.
  • TLR-4 and IL6 expression in the tumor microenvironment were associated with adenocarcinoma in human samples and in the murine model.
  • We found that adenocarcinoma patients (pT1-4) with higher TLR-4 expression in stromal compartment had a significantly increased risk in disease progression.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Apr;134(4):1224-37 [18395100.001]
  • [Cites] Cell Res. 2008 Mar;18(3):334-42 [18301380.001]
  • [Cites] Adv Exp Med Biol. 2008;610:112-27 [18593019.001]
  • [Cites] Adv Cancer Res. 2008;100:203-29 [18620097.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):532-5 [18628760.001]
  • [Cites] BMC Cancer. 2008;8:237 [18702823.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Nov;9(11):1163-70 [18951295.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):267-76 [19211442.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1972-80 [19349357.001]
  • [Cites] Br J Cancer. 2009 May 19;100(10):1589-602 [19436306.001]
  • [Cites] Curr Pharm Des. 2009;15(18):2095-103 [19519447.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):489-99 [19536109.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1073-81 [19468060.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2473-8 [19596916.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6423-9 [19638594.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1110-2 [19671776.001]
  • [Cites] Curr Opin Pharmacol. 2009 Aug;9(4):405-10 [19589728.001]
  • [Cites] Lancet Oncol. 2009 Sep;10(9):877-84 [19656725.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):798-809 [19851315.001]
  • [Cites] Science. 2010 Jan 15;327(5963):291-5 [20075244.001]
  • [Cites] Oncogene. 2010 Feb 11;29(6):781-8 [19946329.001]
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):908-15 [20145615.001]
  • [Cites] Innate Immun. 2010 Apr;16(2):93-103 [19710105.001]
  • [Cites] Cell Immunol. 2010;263(1):79-87 [20346445.001]
  • [Cites] Hepatology. 2010 Jun;51(6):2172-82 [20513002.001]
  • [Cites] Cancer Res. 2010 Jun 1;70(11):4433-42 [20484034.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):333-9 [10752984.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3333-7 [10910033.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):782-7 [10963608.001]
  • [Cites] J Immunol. 2001 Feb 1;166(3):2018-24 [11160251.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] J Pediatr Surg. 2004 Feb;39(2):139-43; discussion 139-43 [14966727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3522-6 [14993616.001]
  • [Cites] J Cell Physiol. 1985 Jul;124(1):107-12 [3876338.001]
  • [Cites] Cytokine. 1992 Jan;4(1):6-11 [1617157.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1882-8 [8137215.001]
  • [Cites] Histochem J. 1995 Sep;27(9):689-93 [8557532.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14833-8 [8962141.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):382-91 [15967832.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):129-39 [15972959.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10637-41 [16322203.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] J Investig Dermatol Symp Proc. 2006 Sep;11(1):36-43 [17069009.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3905-11 [17094421.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1351-7 [17059898.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):439-43 [17466901.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1155-66 [17476345.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6017-21 [17616656.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2614-23 [17724375.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1869-81 [18054559.001]
  • [Cites] Breast Cancer Res. 2007;9(4):212 [17705880.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):31-40 [18087678.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):267-70 [18268042.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):493-8 [18160540.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2704-15 [18565863.001]
  • (PMID = 21059221.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2997091
  •  go-up   go-down


47. Perse M, Zebic A, Cerar A: Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. Scand J Gastroenterol; 2005 Jan;40(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal tumours were evaluated quantitatively and histopathologically for the presence of aberrant crypt foci (ACF), adenomas and adenocarcinomas.
  • However, a significant lower incidence of adenomas (p < 0.05), adenocarcinomas (p < 0.05) and decreased volume of macroscopically visible tumours (by 42%) was found in the experimental group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841716.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


48. Guan J, Chen J, Luo YF, Cao JL, Zhao H, Hao J: [Expression of survivin in colorectal adenoma and adenocarcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun;29(3):398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin in colorectal adenoma and adenocarcinoma].
  • METHODS Immunohistochemistry staining was performed by two-step EnVision technique for the paraffin sections, which included 90 adenomas, 25 ademomas with high-grade glandular intraepithelial neoplasia, and 108 colorectal adenocarcinomas.
  • The positive rate of SVV in tubular adenomas, villous adenomas, and tubulovillous adenomas were 30% (12/40), 40.9% (9/22), and 35.8% (10/28), respectively.
  • The positive rate of SVV in tubulovillous adenomas with high-grade glandular intraepithelial neoplasia were 68% (17/25).
  • SVV expressions among the three types of adenomas without neoplasia were not significantly different (P > 0.05).
  • SVV expression between each type of the above-mentioned ademoma and tubulovillous adenoma with high-grade glandular intraepithelial neoplasia or different Dukes stages of colorectal carcinoma was significantly different (P < 0.05).
  • SVV expressions in adenocarcinomas and adenomas with high grade glandular intraepithelial neoplasia were significantly higher than those in adenomas (P < 0.01).
  • SVV expression may be useful to distinguish adenocarcinoma from adenoma in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633470.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


49. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS: Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci; 2010 Jul;55(7):1955-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.
  • Despite recent medical advancements, gastric adenoma or adenocarcinoma remains a considerable therapeutic challenge.
  • Endoscopic submucosal dissection (ESD) is a more recent approach that is now commonly used for radical resection of gastric adenoma and adenocarcinoma.
  • AIM AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and interleukin-6 (IL-6) are related to the prognosis of gastric adenocarcinoma.
  • However, the expression of these factors in gastric adenoma/adenocarcinoma following ESD has not been clearly evaluated.
  • Here, we report on our study of the expression of VEGF, EGFR, and IL-6 by immunohistochemical staining in extracted tissue from adenoma or adenocarcinoma of the stomach by ESD and subsequent evaluation of the correlation of VEGF, EGFR, and IL-6 with other clinicopathological parameters.
  • The patient cohort consisted of 102 patients with adenoma or adenocarcinoma of the stomach.
  • RESULTS: Immunohistochemical staining for VEGF and IL-6 was significantly higher in both high grade dysplasia and adenocarcinoma than in low grade dysplasia (P < 0.05).
  • Histological differentiation of adenocarcinoma was related to IL-6 expression (P = 0.028).
  • CONCLUSION: The immunohistochemical expression of IL-6 and VEGF can be considered to be useful for clinical diagnosis and follow-up of adenoma or adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Interleukin-6 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):324-31 [14991403.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Pathol. 2000 Jul;191(3):239-44 [10878544.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1123-32 [17363505.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1774-8 [2155059.001]
  • [Cites] J Biomed Sci. 2004 Jul-Aug;11(4):517-27 [15153787.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):455-62 [10809364.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2340-6 [10357403.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Nov;1(6):438-45 [15017643.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):504-9 [18486572.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1823-9 [10430087.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] Am J Obstet Gynecol. 1991 Apr;164(4):1038-42; discussion 1042-3 [2014824.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]
  • [Cites] Oncology. 1995 May-Jun;52(3):182-8 [7715901.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):2008-11 [2592570.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):206-13 [9010092.001]
  • [Cites] Blood. 1989 Sep;74(4):1360-7 [2788466.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1576-7 [7983975.001]
  • [Cites] J Urol. 1992 Dec;148(6):1778-81; discussion 1781-2 [1433606.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):98-106 [9210714.001]
  • [Cites] Jpn J Cancer Res. 1994 Oct;85(10):1045-9 [7525523.001]
  • [Cites] J Surg Oncol. 2001 Oct;78(2):132-7 [11579392.001]
  • [Cites] Immunol Today. 1990 Dec;11(12):443-9 [2127356.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):861-5 [9815760.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1111-5 [10836997.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3547-50 [17094480.001]
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1417-22 [8678006.001]
  • [Cites] J Urol. 1992 Sep;148(3):791-4 [1512827.001]
  • [Cites] Dig Liver Dis. 2008 Aug;40(8):641-9 [18424243.001]
  • [Cites] Science. 1988 Aug 5;241(4866):708-12 [3041594.001]
  • (PMID = 19757047.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


50. Lisovsky M, Falkowski O, Bhuiya T: Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol; 2006 Dec;37(12):1601-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although identification of epithelial dysplasia in Barrett's esophagus (BE) is critically important because of a significant risk of progression to invasive adenocarcinoma, the diagnosis of dysplasia may be challenging.
  • It is expressed in colon adenomas and adenocarcinomas but not in normal colonic epithelium suggesting a role in development of gastrointestinal malignancies.
  • Ninety-six routinely processed biopsy and/or resection specimens (23 negative for dysplasia; 19, low-grade dysplasia; 22, high-grade dysplasia; 16, reactive atypia; and 16, esophageal adenocarcinoma) were immunostained using a monoclonal anti-AMACR antibody p504S.
  • Of 16 specimens, 12 (75%) showed positive staining for AMACR in the adenocarcinoma group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996568.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


51. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF: Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis; 2010 Jan;25(1):17-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas.
  • This study was to detect expressions of the two genes in colorectal adenomas and carcinomas and to analyze the correlation between Musashi-1 and beta1-integrin.
  • METHODS: Musashi-1 and beta1-integrin immunoreactivity was studied immunohistochemically in tissue microarray-based samples containing 69 colorectal adenocarcinomas, eight normal mucosa, and eight adenomas, and their messenger RNA (mRNA) expression level was detected by RT-PCR in resected specimens including the three types of tissue.
  • RESULTS: A percentage of 66.7% (46/69) and 59.2% (41/69) of colorectal adenocarcinomas were immunoreactive with Musashi-1 and beta1-integrin, respectively.
  • beta1-integrin expression was higher in group of adenocarcinomas than that of adenomas (P = 0.0276).
  • Significant differences of Musashi-1 and beta1-integrin mRNA expression levels were found between the normal colorectal mucosa, adenoma, and adenocarcinoma tissues (P = 0.01; P = 0.03, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Antigens, CD29 / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nerve Tissue Proteins / genetics. RNA-Binding Proteins / genetics. Stem Cells / metabolism


52. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


53. Cho EY, Kim KM, Park CK, Kim JJ, Sohn TS, Kim DW: AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas. APMIS; 2007 Jun;115(6):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
  • Alpha-methylacyl-CoA racemase (AMACR) is a novel tumor biomarker expressed in a number of neoplasms, including colorectal and prostatic adenocarcinomas.
  • Using immunohistochemistry we studied the expression of AMACR in normal gastric mucosa (n=32), intestinal metaplasia (n=26), adenomas (n=29) and adenocarcinomas (n=132) of the stomach from 135 patients.
  • Synchronous adenocarcinomas arising in the background of adenomas were observed in 26 cases.
  • Tissue from intestinal metaplasia, adenomas, and adenocarcinomas was positive in 7.7% (2/26), 79.3% (23/29), and 62.9% (83/132) of cases, respectively.
  • The difference in AMACR expression between adenomas or adenocarcinomas and non-neoplastic mucosa was statistically significant (p=0.0001).
  • Our results indicate that as well as being an additional diagnostic tool, altered AMACR expression in gastric adenomas and intestinal-type carcinomas suggests that AMACR may be involved early in the development of intestinal-type gastric carcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / analysis. Intestinal Neoplasms / metabolism. Intestines / pathology. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550379.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


54. Kucherlapati MH, Yang K, Fan K, Kuraguchi M, Sonkin D, Rosulek A, Lipkin M, Bronson RT, Aronow BJ, Kucherlapati R: Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A; 2008 Oct 7;105(40):15493-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large intestinal tumors are predominantly adenomas, whereas the tumors of the small intestine are a mixture of adenomas and adenocarcinomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Aug 28;25(38):5302-8 [16936751.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):638-47 [16258171.001]
  • [Cites] Genome Biol. 2007;8(7):R131 [17615082.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1363-80 [18403596.001]
  • [Cites] PLoS Genet. 2008 Jun;4(6):e1000092 [18551179.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):217-29 [10882064.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6297-302 [11507085.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):751-63 [12198702.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):109-14 [12556968.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1189-95 [15492985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Int J Cancer. 1981 Oct 15;28(4):431-40 [7309289.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Dec;29(2):289-301 [3479234.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Science. 1989 Apr 14;244(4901):207-11 [2565047.001]
  • [Cites] Princess Takamatsu Symp. 1989;20:49-59 [2562187.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1805-15 [10430085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6 [7753829.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3576-83 [16585182.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1061-6 [16570290.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):1-12 [9671308.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1575-81 [9893631.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] FASEB J. 1993 Jul;7(10):931-7 [8344490.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] PLoS Genet. 2006 Sep 15;2(9):e146 [17002498.001]
  • (PMID = 18832169.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084301; United States / NCI NIH HHS / CA / CA-084301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Other-IDs] NLM/ PMC2563082
  •  go-up   go-down


55. Kim SJ, Lee HW, Kim DC, Rha SH, Hong SH, Jeong JS: Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater. Pathol Int; 2008 Apr;58(4):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater.
  • Twenty-one (58.3%) of 36 adenocarcinomas and three (17.6%) of 17 adenomas had GLUT1 immunoreactivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Ampulla of Vater / metabolism. Common Bile Duct Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324916.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human
  •  go-up   go-down


56. Goere D, Elias D: [Appendiceal tumors found at appendectomy]. J Chir (Paris); 2009 Oct;146 Spec No 1:36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are three main histologic types of appendiceal tumor: adenoma, adenocarcinoma, and neuroendocrine tumor.
  • Adenomas and adenocarcinomas are both rare; they share two particularities: (a) a mucinous component is both frequent and predominant, (b) they have a tendency to intraperitoneal dissemination.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenoma / diagnosis. Adenoma / surgery. Humans. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / surgery. Peritoneal Neoplasms / prevention & control. Pseudomyxoma Peritonei / prevention & control. Rupture / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846099.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 7
  •  go-up   go-down


57. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • TIMP-1 mRNA was detected in 2 of 7 adenomatous polyps in the adenoma area: in both cases associated with focal stromal inflammation at the epithelial-stromal interface.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


58. Pollard RE, Reilly CM, Uerling MR, Wood FD, Feldman EC: Cross-sectional imaging characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988-2006). J Vet Intern Med; 2010 Jan-Feb;24(1):160-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-sectional imaging characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988-2006).
  • BACKGROUND: Pituitary tumors in dogs can be adenomas, invasive adenomas, or adenocarcinomas.
  • In people, invasive adenomas and pituitary adenocarcinomas carry a worse prognosis than adenomas.
  • HYPOTHESIS/OBJECTIVE: To identify differentiating features on cross-sectional imaging in dogs with pituitary adenomas, invasive adenomas, and adenocarcinomas.
  • ANIMALS: Thirty-three dogs that had computed tomography (CT) or magnetic resonance imaging (MRI) performed and a necropsy diagnosis of pituitary adenoma (n = 20), invasive adenoma (n = 11), or adenocarcinoma (n = 2).
  • RESULTS: Mean (+/- standard deviation) age for dogs with pituitary adenomas (10.6 +/- 2.9 years) was greater than that of those with invasive adenomas (8.3 +/- 2.7 years, P = .04).
  • Eighteen out of 20 (90%) dogs with adenomas had contrast-enhancing masses.
  • Mean adenoma height was 1.2 +/- 0.7cm.
  • Eight out of 20 (40%) adenomas were round and 8/20 (40%) compressed surrounding brain.
  • Eleven out of 11 dogs (100%) with invasive adenomas had contrast-enhancing masses.
  • Mean invasive adenoma height was 1.8 +/- 0.7 cm, which was significantly greater than adenomas (P = .03).
  • Clinical and imaging features were variable for 2 dogs with adenocarcinomas.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Invasive adenoma should be suspected if a dog with a pituitary tumor is <7.7 years of age and has a mass > 1.9 cm in vertical height.
  • Adenocarcinomas are uncommon and metastatic lesions were not seen with imaging.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925577.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


59. Cao J, Xia J, Wang H, DU H, Li WL: [Fragile histidine triad protein expression and correlation with apoptosis in rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Mar;10(2):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarray and immunohistochemistry SP were used to detect the expression of FHIT, Bcl-2, Bax and Survivin in 16 cases of normal rectal tissue, 16 cases of rectal adenoma and 80 cases of rectal carcinoma.
  • RESULTS: The positive rates of FHIT expression in normal rectal tissue, rectal adenoma and adenocarcinoma were 93.8%, 75.0% and 46.3% respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380463.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / bcl-2-Associated X Protein; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


60. Park SH, Kim SY, Lee SS, Bogoni L, Kim AY, Yang SK, Myung SJ, Byeon JS, Ye BD, Ha HK: Sensitivity of CT colonography for nonpolypoid colorectal lesions interpreted by human readers and with computer-aided detection. AJR Am J Roentgenol; 2009 Jul;193(1):70-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A computerized database search for a 33-month period found 21 patients who had undergone both colonoscopy and CTC and who had a total of 23 genuinely nonpolypoid colorectal lesions: eight adenomas (9-30 mm in width), 10 stage Tis or T1 adenocarcinomas (10-25 mm), and five nonadenomatous lesions (8-20 mm).
  • RESULTS: The sensitivities of human readers for nonpolypoid adenomatous lesions (i.e., both adenomas and adenocarcinomas), adenocarcinomas, and nonadenomatous lesions were 66.7% (12/18), 90% (9/10), and 0% (0/5), respectively.
  • A 10-mm stage T1 adenocarcinoma was missed by a human reader on blinded review but was detected with CAD.
  • Both human readers and CAD yielded significantly higher sensitivity for adenomatous lesions than for nonadenomatous lesions (p = 0.014 and 0.046, respectively) and for adenocarcinomas than for noncancerous lesions (p = 0.003 and 0.0001, respectively).
  • CONCLUSION: CTC showed a high sensitivity for nonpolypoid stage Tis and T1 adenocarcinomas 10 mm or greater in width despite the limited overall sensitivity for nonpolypoid adenomatous lesions, when performed using cathartic preparation and fecal tagging.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542397.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Wilkins T, LeClair B, Smolkin M, Davies K, Thomas A, Taylor ML, Strayer S: Screening colonoscopies by primary care physicians: a meta-analysis. Ann Fam Med; 2009 Jan-Feb;7(1):56-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean estimated adenoma and adenocarcinoma detection rates were 28.9% (95% confidence interval [CI], 20.4%-39.3%) and 1.7% (95% CI, 0.9%-3.0%), respectively.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):868-77 [10763931.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] JAMA. 2000 Apr 19;283(15):2008-12 [10789670.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):524-7 [10805835.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):573-84 [11033584.001]
  • [Cites] Surg Endosc. 2001 Mar;15(3):251-61 [11344424.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):129-31 [12118971.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):352-7 [12612515.001]
  • [Cites] Am J Med. 2003 Aug 1;115(2):129-33 [12893399.001]
  • [Cites] J Am Board Fam Pract. 2004 Sep-Oct;17(5):353-8 [15355949.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):946-51 [1858758.001]
  • [Cites] Fam Pract Res J. 1992 Sep;12(3):313-20 [1414436.001]
  • [Cites] Fam Pract Res J. 1993 Mar;13(1):43-52 [8484340.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Gastrointest Endosc. 1995 Oct;42(4):287-91 [8536893.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] J Fam Pract. 1996 Dec;43(6):561-6 [8969704.001]
  • [Cites] J Fam Pract. 1997 May;44(5):473-80 [9152265.001]
  • [Cites] Fam Med. 1997 Sep;29(8):575-9 [9310757.001]
  • [Cites] Tenn Med. 1998 Jan;91(1):21-6 [9439182.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] JAMA. 1999 Sep 15;282(11):1054-60 [10493204.001]
  • [Cites] Can J Rural Med. 2004 Spring;9(2):89-93 [15603681.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):31-44; quiz 55-6 [15661685.001]
  • [Cites] Ann Fam Med. 2005 Mar-Apr;3(2):122-5 [15798037.001]
  • [Cites] Can Fam Physician. 2005 Sep;51:1224-8 [16190175.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4 Suppl):S16-28 [16564908.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [ErratumIn] Ann Fam Med. 2009 Mar-Apr;7(2):181
  • (PMID = 19139450.001).
  • [ISSN] 1544-1717
  • [Journal-full-title] Annals of family medicine
  • [ISO-abbreviation] Ann Fam Med
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 2 D12 HP 00023-04
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  • [Other-IDs] NLM/ PMC2625839
  •  go-up   go-down


62. Han HS, Lee SY, Seong MK, Kim JH, Sung IK, Park HS, Jin CJ, Hwang TS: Presence of iron in colorectal adenomas and adenocarcinomas. Gut Liver; 2008 Jun;2(1):19-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of iron in colorectal adenomas and adenocarcinomas.
  • In this study, we attempted to determine the significance of tissue iron in colorectal adenomas and adenocarcinomas.
  • METHODS: This study investigated 138 colorectal neoplasms (54 adenocarcinomas, 25 adenomas with high-grade dysplasia, and 59 adenomas with low-grade dysplasia) that were removed by surgical or endoscopic resection in Konkuk University Hospital between August 2005 and August 2006.
  • RESULTS: Positive Perls' staining was evident in 35.2% (19/54) of the adenocarcinomas and 22.6% (19/84) of the adenomas, and in only 2.2% (3/138) of the samples of adjacent normal colon tissue (p<0.001).
  • Iron expression was strong in larger (p=0.004) and pedunculated (p<0.001) adenomas, and in all types of adenocarcinomas regardless of their size, shape, and location.
  • CONCLUSIONS: The frequent presence of iron in the stroma of large adenomas, pedunculated adenomas, and adenocarcinomas indicates that iron deposition is a secondary phenomenon to intralesional hemorrhage rather than a consequence of epithelial-cell carcinogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2006 Oct;55(10):1384-6 [16966697.001]
  • [Cites] Gut. 2006 Oct;55(10):1449-60 [16641131.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):1004-9 [16733117.001]
  • [Cites] Dig Dis Sci. 2005 Apr;50(4):696-707 [15844705.001]
  • [Cites] Biol Trace Elem Res. 2003 Oct;95(1):19-28 [14555796.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):503-7 [8827353.001]
  • [Cites] J Natl Cancer Inst. 1994 Mar 16;86(6):455-60 [8120921.001]
  • [Cites] Histol Histopathol. 1992 Oct;7(4):543-7 [1457975.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1333-6 [15362746.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s211-3 [15655626.001]
  • (PMID = 20485606.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871572
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenoma / Colorectal neoplasm / Iron
  •  go-up   go-down


63. Wang JY, Yeh CS, Tzou WS, Hsieh JS, Chen FM, Lu CY, Yu FJ, Cheng TL, Huang TJ, Lin SR: Analysis of progressively overexpressed genes in tumorigenesis of colorectal cancers using cDNA microarray. Oncol Rep; 2005 Jul;14(1):65-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, cDNA microarray technology was used to identify colorectal tumor-related functional genes, which are overexpressed continuously from colorectal adenoma to adenocarcinoma.
  • Furthermore, the gradually over-expressed genes from adenoma to adenocarcinoma were validated by Northern blot analysis with additional samples from three patients with synchronous colorectal adenocarcinoma and adenoma and four patients with CRC.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944769.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger
  •  go-up   go-down


64. Woicke J, Durham SK, Mense MG: Lobucavir-induced proliferative changes in mice. Exp Toxicol Pathol; 2007 Nov;59(3-4):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Light microscopically, lobucavir-induced neoplastic lesions consisted of upper digestive tract squamous cell neoplasia in males and females; cervical, vaginal, and cutaneous squamous cell neoplasia in females; and Hardarian gland adenomas and adenocarcinomas in male mice.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942294.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Carcinogens; 5Z93L87A1R / Guanine; 8U5PYQ1R2E / lobucavir
  •  go-up   go-down


65. Doris K, Karabela SP, Kairi CA, Simoes DC, Roussos C, Zakynthinos SG, Kalomenidis I, Blackwell TS, Stathopoulos GT: Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice. Respir Res; 2010;11:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethane resulted in formation of atypical alveolar hyperplasias, adenomas, and adenocarcinomas in mouse lungs.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):139-44 [12957351.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):327-34 [12846363.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Lancet. 2004 Aug 21-27;364(9435):709-21 [15325838.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] J Epidemiol Community Health. 1978 Dec;32(4):303-13 [744822.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Cancer Res. 1992 May 1;52(9 Suppl):2670s-2676s [1562998.001]
  • [Cites] Immunity. 1996 Jan;4(1):15-24 [8574848.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):541-55 [9659582.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1583-4 [9811301.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210 [10413421.001]
  • [Cites] J Asthma. 2005 Sep;42(7):597-600 [16169796.001]
  • [Cites] Cancer Causes Control. 2006 Apr;17(3):349-50 [16489542.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1240-4 [16344268.001]
  • [Cites] J Leukoc Biol. 2006 Jun;79(6):1131-9 [16617160.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Jun 15;173(12):1414-5; author reply 1415 [16760359.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Curr Allergy Asthma Rep. 2007 Jun;7(3):231-6 [17448336.001]
  • [Cites] Nat Med. 2007 May;13(5):570-8 [17435770.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55 [17507545.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Proc Am Thorac Soc. 2007 Oct 1;4(7):512-21 [17878463.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Eur Respir J. 2002 Jan;19(1):127-33 [11843311.001]
  • [Cites] Nat Rev Immunol. 2008 Mar;8(3):218-30 [18274559.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Eur Respir J. 2008 Oct;32(4):1068-81 [18827153.001]
  • [Cites] Nat Med. 2008 Oct;14(10):1023-4 [18841139.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Apr;40(4):443-53 [18927348.001]
  • [Cites] Eur Respir J. 2009 May;33(5):974-85 [19213792.001]
  • [Cites] Am J Respir Crit Care Med. 2009 May 15;179(10):894-902 [19234104.001]
  • [Cites] Arch Intern Med. 2009 Jun 8;169(11):1022-3 [19506169.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):173-4 [19732714.001]
  • [Cites] Nature. 2009 Nov 5;462(7269):104-7 [19847165.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):89-97 [20129250.001]
  • [Cites] Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81 [20595227.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Mol Carcinog. 2003 Nov;38(3):117-23 [14587096.001]
  • (PMID = 20796309.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3IN71E75Z5 / Urethane
  • [Other-IDs] NLM/ PMC2936383
  •  go-up   go-down


66. Matusiewicz M, Krzystek-Korpacka M, Diakowska D, Grabowski K, Augoff K, Blachut K, Paradowski L, Kustrzeba-Wojcicka I, Piast M, Banas T: Serum sulfatase activity is more elevated in colonic adenomas than cancers. Int J Colorectal Dis; 2008 Apr;23(4):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sulfatase activity is more elevated in colonic adenomas than cancers.
  • Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas.
  • The activity was more elevated in adenomas (149; 128-173 U) than in cancers (103; 90-112 U).
  • Sulfatase activity exceeded the cutoff value in 71% of AP and 47% of CRC patients.
  • It increased with number of adenomas and tended to decrease with tumor progression.
  • Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1991 Dec 31;204(1-3):69-77 [1687888.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Neoplasma. 2002;49(1):10-5 [12044053.001]
  • [Cites] J Pediatr. 1975 Apr;86(4):574-6 [805221.001]
  • [Cites] Clin Biochem. 2004 Aug;37(8):673-8 [15302609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):568-73 [11805315.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:355-79 [16124866.001]
  • [Cites] Cancer. 1975 Dec;36(6 Suppl):2337-45 [1212650.001]
  • [Cites] Mol Cancer. 2005 Apr 07;4(1):14 [15817123.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4833-8 [15051888.001]
  • [Cites] Pol Merkur Lekarski. 2004 Sep;17(99):252-4 [15628052.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):95-101 [11295292.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):365-79 [15691635.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] World J Gastroenterol. 1998 Feb;4(1):52-54 [11819231.001]
  • (PMID = 18193432.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


67. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, Okanoue T, Hattori T: Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci; 2005 Sep;50(9):1741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.
  • The entity of serrated adenoma of the colorectum was first proposed in 1990, and it was characterized as epithelial neoplasia combining the architectural features of a hyperplastic polyp with the cytological features of an adenoma.
  • Over the past few years, various clinicopathological studies on serrated adenoma have been reported, but its histogenesis remains unclear.
  • Recently the existence of a "serrated neoplasia pathway" leading to malignancy, which is different from the so-called adenoma-carcinoma sequence, has been discussed.
  • Yao et al. reported that hyperplastic polyps and serrated adenomas share a common cell lineage with gastric differentiation.
  • To clarify the existence of the serrated neoplasia pathway, we performed immunohistochemical staining of cytokeratin 7 (CK7) and cytokeratin 20 (CK20), which are commonly used to determine the primary site of a metastatic lesion, and we examined the pattern of CK7/CK20 expression in various colorectal lesions including 44 serrated adenomas, 25 hyperplastic polyps, 20 traditional adenomas, and 48 carcinomas.
  • An obvious difference existed in the pattern of CK7/CK20 expression between the serrated lesions (hyperplastic polyps and serrated adenomas) and others.
  • The majority of serrated adenomas and hyperplastic polyps presented a CK7+/CK20+ pattern, whereas most conventional adenomas and adenocarcinomas expressed CK7-/CK20+.
  • Adenocarcinoma developing in serrated adenoma also presented a CK7+/CK20+ pattern.
  • Taken together with the present results, a distinct pathway of colorectal carcinogenesis must exist, which is different from the adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Intermediate Filament Proteins / biosynthesis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] J Pathol. 2000 Mar;190(4):444-9 [10699993.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Acta Histochem. 1991;91(1):21-3 [1724863.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Gut. 2002 Aug;51(2):200-6 [12117880.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):512-22 [11710638.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:282-306 [2417517.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):445-54 [11962749.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):215-20 [11328539.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] J Pathol. 1999 Apr;187(5):511-7 [10398114.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] J Pathol. 1991 Oct;165(2):145-52 [1720817.001]
  • (PMID = 16133982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


68. Han YD, Hong YK, Kang JG, Choi YJ, Park CH: Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. J Korean Soc Coloproctol; 2010 Oct;26(5):339-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
  • METHODS: Fifty colorectal adenomas and forty adenocarcinomas were investigated by using immunohistochemical staining for COX-2, VEGF and EGFR.
  • The correlations of COX-2, VEGF and EGFR with the grade of dysplasia, the size of the adenoma, and various clinicopathologic factors were studied.
  • COX-2 and EGFR showed correlations with adenomas rather than adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152137.001).
  • [ISSN] 2093-7830
  • [Journal-full-title] Journal of the Korean Society of Coloproctology
  • [ISO-abbreviation] J Korean Soc Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2998021
  • [Keywords] NOTNLM ; Adenocarcinoma / Colorectal carcinoma / Cyclooxygenase 2 / Endothelial growth factor receptor / Vascular endothelial growth factor
  •  go-up   go-down


69. Diehl D, Oesterle D, Elmlinger MW, Hoeflich A, Wolf E, Lahm H: IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment. J Carcinog; 2006;5:24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant crypt foci (ACF) served as markers of early lesions in the colonic mucosa, whereas adenomas and carcinomas characterized the endpoints of tumor development.
  • Nevertheless, adenomas and adenocarcinomas of the colon, present after 34 weeks in both genetic groups, were not found at different frequency.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21092-8 [12657632.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] Lancet. 1992 Sep 12;340(8820):626-30 [1355210.001]
  • [Cites] Cell Struct Funct. 2003 Aug;28(4):255-63 [14586135.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):862-6 [14624779.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2642-9 [14669304.001]
  • [Cites] Carcinogenesis. 2004 Apr;25(4):527-33 [14688025.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1600-3 [14996716.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Apr;288(4):F703-13 [15572521.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1236-40 [2917353.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6187-92 [3167865.001]
  • [Cites] Endocrinology. 1994 Nov;135(5):1877-86 [7525257.001]
  • [Cites] Exp Cell Res. 1995 Feb;216(2):342-51 [7531153.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] J Pathol. 1995 May;176(1):37-44 [7616355.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3141-53 [15735679.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1819-22 [16030122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15593-8 [16230630.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):561-71 [16375662.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):287-94 [1706308.001]
  • [Cites] Carcinogenesis. 1991 Nov;12(11):2093-8 [1934294.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):624-30 [1991846.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):452-9 [8050827.001]
  • [Cites] Mutagenesis. 1996 May;11(3):241-5 [8671746.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):781-90 [9797687.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1276-80 [9809551.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):509-13 [10190570.001]
  • [Cites] Gut. 1999 May;44(5):704-8 [10205209.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3278-88 [10207053.001]
  • [Cites] Immunol Cell Biol. 1999 Jun;77(3):256-62 [10361258.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):15-7 [10449601.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1070-6 [10706126.001]
  • [Cites] Cell Prolif. 2000 Feb;33(1):1-18 [10741640.001]
  • [Cites] Toxicol Lett. 2000 Jun 5;115(3):205-12 [10814890.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1117-20 [10836998.001]
  • [Cites] Growth Horm IGF Res. 1998 Jun;8(3):185-93 [10984306.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1344-50 [11044360.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):901-5 [12223436.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38239-44 [12154096.001]
  • [Cites] Growth Horm IGF Res. 2002 Feb;12(1):69-79 [12127304.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7318-24 [11585772.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):315-20 [11181454.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]
  • (PMID = 17118177.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660565
  •  go-up   go-down


70. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, Marchesi F, Thirunarayanan N, Vischer HF, Qin L, Mayer L, Harpaz N, Leurs R, Furtado GC, Clevers H, Tortorella D, Smit MJ, Lira SA: The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest; 2010 Nov;120(11):3969-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VS28 mice showed a hyperplastic intestinal epithelium and, strikingly, developed adenomas and adenocarcinomas by 40 weeks of age.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):741-50 [9049319.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34183-9 [10940307.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1133-7 [11050102.001]
  • [Cites] J Virol. 2001 Jul;75(13):5949-57 [11390596.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Cytokine. 2002 Jul 7;19(1):37-46 [12200112.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1557-63 [12443594.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Pharmacol Ther. 2003 Jun;98(3):269-97 [12782241.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1331-6 [14691920.001]
  • [Cites] Neuropsychopharmacology. 2004 Mar;29(3):441-9 [14628000.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):243-7 [15219948.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):401-8 [9200479.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] J Exp Med. 1998 Sep 7;188(5):855-66 [9730887.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):209-14 [9883886.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:59-88 [9891778.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6476-82 [10037740.001]
  • [Cites] J Gen Virol. 1999 Mar;80 ( Pt 3):543-7 [10091991.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):331-6 [10433925.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):244-9 [15842049.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Int Immunol. 2005 Aug;17(8):1023-34 [16000328.001]
  • [Cites] FEBS J. 2005 Aug;272(16):4163-77 [16098198.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2537-48 [16219459.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jan;27(1):56-63 [16352349.001]
  • [Cites] J Intern Med. 2006 Mar;259(3):219-46 [16476101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73 [16924106.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2295-300 [17035736.001]
  • [Cites] J Neurovirol. 2007;13(1):85; author reply 86-7 [17454453.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1133-9 [17341657.001]
  • [Cites] Nat Protoc. 2007;2(8):1998-2004 [17703211.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):849-64 [18325394.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):83-7 [18488086.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):378-88 [18338378.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):1-9 [19107226.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2861-9 [19318580.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1680-8.e7 [19208363.001]
  • [Cites] Virology. 2009 Sep 15;392(1):1-10 [19720205.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):692-701 [19570946.001]
  • [Cites] Lancet. 1978 May 6;1(8071):957-60 [76890.001]
  • [Cites] Intervirology. 1979;12(2):84-8 [231587.001]
  • [Cites] Intervirology. 1980;14(3-4):223-7 [7239857.001]
  • [Cites] Int J Cancer. 1981 May 15;27(5):659-67 [6270021.001]
  • [Cites] Gut. 1982 Jan;23(1):21-30 [6276266.001]
  • [Cites] Intervirology. 1981;16(4):244-9 [6282775.001]
  • [Cites] Klin Wochenschr. 1985 May 2;63(9):405-8 [2987605.001]
  • [Cites] Gut. 1985 Oct;26(10):1053-8 [2996990.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):741-50 [2836142.001]
  • [Cites] Science. 1990 Feb 2;247(4942):561-4 [1689075.001]
  • [Cites] Cell. 1993 Feb 12;72(3):415-25 [7679328.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28539-42 [7961796.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):40-50 [7806062.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 6;211(1):325-30 [7540006.001]
  • [Cites] J Pathol. 1996 Feb;178(2):201-6 [8683390.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • (PMID = 20978345.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122665002; United States / NIDDK NIH HHS / DK / P01 DK072201; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ORF74 protein, Human herpesvirus 8; 0 / Receptors, Chemokine; 0 / US28 receptor, Cytomegalovirus; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2964974
  •  go-up   go-down


71. Toth B, Coles M, Lynch J: Effects of VPS extract of Coriolus versicolor on cancer of the large intestine using a serial sacrifice technique. In Vivo; 2006 May-Jun;20(3):341-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, the tumors were diagnosed as polypoid adenomas and adenocarcinomas of the cecum, colon and rectum.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Cecal Neoplasms / chemically induced. Cecal Neoplasms / pathology. Colonic Neoplasms / chemically induced. Colonic Neoplasms / pathology. Female. Injections, Subcutaneous. Mice. Rectal Neoplasms / chemically induced. Rectal Neoplasms / pathology. Survival Analysis. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724667.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 1R21 AT001739
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Plant Extracts; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


72. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H: The Intestinal Wnt/TCF Signature. Gastroenterology; 2007 Feb;132(2):628-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Independently, differential gene-expression profiles of human adenomas and adenocarcinomas vs normal colonic epithelium were obtained.
  • RESULTS: Expression analyses of approximately 80 genes common between these data sets were performed in a murine adenoma model.
  • CONCLUSIONS: The genes were invariably expressed in adenomas, yet could be subdivided into 3 modules, based on expression in distinct crypt compartments.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Animals. Cell Line, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression Profiling. Humans. Mice. Oligonucleotide Array Sequence Analysis. Paneth Cells / metabolism. RNA, Messenger / metabolism. T Cell Transcription Factor 1 / metabolism. Time Factors. Transcription Factor 7-Like 2 Protein. Transfection. beta Catenin / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320548.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / T Cell Transcription Factor 1; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Tcf7l2 protein, mouse; 0 / Transcription Factor 7-Like 2 Protein; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


73. Shen J, Liu J, Xie Y, Diwan BA, Waalkes MP: Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure. Toxicol Sci; 2007 Feb;95(2):313-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure.
  • Lung adenoma and adenocarcinoma from adult female mice exposed to arsenic in utero showed widespread, intense nuclear ER-alpha expression.
  • In contrast, normal adult lung and diethylnitrosamine-induced lung adenocarcinoma showed little evidence of ER-alpha expression.
  • ER-alpha activation was specifically associated with arsenic-induced lung adenocarcinoma and adenoma but not with nitrosamine-induced lung tumors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Feb;190(2):133-42 [10657010.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1243-55 [14617798.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):259-67 [15161576.001]
  • [Cites] Clin Lung Cancer. 2004 May;5(6):353-9 [15217534.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):261-9 [15231294.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):366-76 [15276416.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Jan;32(1):65-71 [15514114.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):316-9 [15627066.001]
  • [Cites] J Soc Gynecol Investig. 2005 Jan;12(1):58-64 [15629674.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1459-70 [15735034.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3796-805 [15867376.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3212-8 [15886308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11287-91 [16357134.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Sci. 2006 Jun;91(2):372-81 [16543296.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Annu Rev Med. 2003;54:73-87 [12471176.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35 [12503217.001]
  • [Cites] Biochem Cell Biol. 2002;80(3):335-41 [12123286.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):236-44 [12111698.001]
  • [Cites] Lung Cancer. 2002 May;36(2):125-32 [11955646.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):46-53 [11940206.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40 [11911952.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • (PMID = 17077188.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / NIH0011069698; United States / Intramural NIH HHS / / ; United States / PHS HHS / / NIH0011069698; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Carcinogens, Environmental; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite
  • [Other-IDs] NLM/ NIHMS33564; NLM/ PMC2692318
  •  go-up   go-down


74. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H: Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis; 2009 Jun;24(6):613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Estrogen receptor alpha (ER alpha), ER beta, AIB1, and TIF2 protein expression were evaluated by immunohistochemistry in colorectal normal mucosa, adenomas, and adenocarcinomas from 110 patients with colorectal cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Colorectal Dis. 2009 Dec;24(12):1479 [19479269.001]
  • [Cites] Cell. 2002 Dec 27;111(7):931-41 [12507421.001]
  • [Cites] J Cell Biochem. 2007 Aug 1;101(5):1125-47 [17520659.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):512-8 [10690532.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2336-42 [11356680.001]
  • [Cites] Genes Dev. 2004 Oct 1;18(19):2315-35 [15466484.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2366-72 [17332369.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7993-8002 [16140972.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1535-65 [11581496.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):416-22 [16130938.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5157-71 [15169882.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1043-50 [15522549.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):1-6 [11774236.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5222-6 [16963027.001]
  • [Cites] J Mol Endocrinol. 2003 Feb;30(1):13-29 [12580758.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3810-23 [16648476.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):69-74 [16458427.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):1-14 [16084012.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8373-81 [16951146.001]
  • [Cites] Br J Surg. 2000 Dec;87(12):1684-9 [11122185.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):940-4 [11567223.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23763-8 [11328819.001]
  • [Cites] Acta Pharmacol Sin. 2006 Apr;27(4):387-94 [16539836.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):2080-5 [10372714.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):777-83 [16084947.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6134-42 [15448000.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):22-31 [17045797.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):17-21 [15944762.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 13;270(2):425-31 [10753641.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1823-32 [1451976.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):193-204 [12725419.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2346-52 [12436441.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1928-36 [11747336.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1694-702 [15477865.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):329-37 [18172327.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1593-605 [16980945.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3A):1037-41 [8074447.001]
  • [Cites] J Nutr. 2004 Jan;134(1):179-82 [14704314.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7742-55 [14560019.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):11039-46 [17108143.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2554-61 [18246597.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):217-23 [10861496.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):632-40 [11212261.001]
  • [Cites] Mol Endocrinol. 2001 May;15(5):783-96 [11328858.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3667-75 [8670870.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2720-8 [12498292.001]
  • [Cites] EMBO J. 2006 Jun 7;25(11):2453-64 [16675958.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4287-92 [16309230.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 14;229(1-2):39-47 [15607527.001]
  • [Cites] Horm Metab Res. 2001 Mar;33(3):121-6 [11355743.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1980-9 [12796359.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):677-84 [9192892.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):245-8 [10667568.001]
  • [Cites] Mol Cell. 2007 Sep 7;27(5):691-700 [17803935.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 9;247(1):75-8 [9636657.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1479-86 [16533771.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):64-73 [18162290.001]
  • [Cites] J Pathol. 1998 Feb;184(2):153-60 [9602706.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):303-311 [18464259.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):113-9 [11815408.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):521-7 [10425218.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1405-11 [17332282.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):257-60 [15225781.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7976-83 [16140970.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4516-21 [8813150.001]
  • [Cites] J Pathol. 2005 Sep;207(1):53-60 [15954165.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • (PMID = 19198856.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Nuclear Receptor Coactivator 2; 0 / Trans-Activators; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


75. Gui X, Guzman G, Dobner PR, Kadkol SS: Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides; 2008 Sep;29(9):1609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma.
  • NT is expressed in fetal but not differentiated colonic epithelium and is re-expressed in colonic adenocarcinoma.
  • To further understand the possible role of NTSR1 expression in colonic tumorigenesis and progression, we examined NTSR1 mRNA by in situ hybridization in normal colonic mucosa, adenomas, and colonic adenocarcinomas.
  • NTSR1 mRNA expression was undetectable or weak in superficial differentiated epithelial cells of normal colonic epithelium, but adenomas and adenocarcinomas showed moderate to strong expression (p<0.05).
  • Adenocarcinomas showed a higher level of expression compared to adenomas (p<0.05).
  • Furthermore, adenocarcinomas that infiltrated into and beyond the muscularis propria showed a higher intensity of NTSR1 expression compared with tumors that were localized to the mucosa or submucosa.
  • These results suggest that increased NTSR1 expression may be an early event during colonic tumorigenesis and also contribute to tumor progression and aggressive behavior in colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Receptors, Neurotensin / biosynthesis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541341.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor
  •  go-up   go-down


76. Wang LP, Yang GZ, Zhou ZY, Li L, Gao BL, Chen J: [Clinicopathologic features and proliferative status of colorectal serrated lesions: a study of 104 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Feb;38(2):100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features and proliferative status of colorectal hyperplastic polyp (HP), sessile serrated adenoma (SSA) and traditional serrated adenoma (TSA).
  • RESULTS: On the basis of morphologic examination, 60 cases were classified as HP, 20 cases as TSA, 11 cases as SSA, 7 cases as mixed HP/SSA/TSA, and 6 cases as mixed serrated polyp/adenoma and tubular adenoma.
  • The number and distribution of Ki-67 positive cells in SSA were similar to those in TSA but were significantly different from those in tubular adenoma and adenocarcinoma (chi2=34.601, P=0.000; chi2=63.077, P=0.000, respectively).
  • In general, the proliferative index is lower in serrated adenoma (TSA or SSA) than in tubular adenoma.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Intestinal Polyps / pathology. Ki-67 Antigen / metabolism
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Adult. Aged. Aged, 80 and over. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Young Adult


77. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ: Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol; 2009 Apr;40(4):443-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung lesions in CCSP(Cre-Neo)/LSL-K-ras(G12D) and CCSP(Cre)/LSL-K-ras(G12D) mice appeared at 4 and 1 month of age, respectively, and were classified as epithelial hyperplasia of the bronchioles, adenoma, and adenocarcinoma.

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5054-8 [15289303.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Dec 1;164(11):2114-9 [11739144.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):949-57 [11698399.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2 [11866137.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Eur Respir J. 2002 Sep;20(3):556-63 [12358328.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45547-57 [12237307.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 15;167(4):587-92 [12433671.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94 [15191915.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Med Clin North Am. 2004 Nov;88(6):1535-52, xi [15464112.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):433-9 [15489136.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Am J Physiol. 1991 Aug;261(2 Pt 1):L70-6 [1872417.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(13):23-9 [1327034.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] J Leukoc Biol. 1995 Mar;57(3):375-8 [7884307.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1316-20 [7551388.001]
  • [Cites] J Histochem Cytochem. 1996 Aug;44(8):919-27 [8756763.001]
  • [Cites] Toxicol Lett. 1996 Nov;88(1-3):109-13 [8920724.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] Chest. 1997 Apr;111(4):885-90 [9106565.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1015-22 [10596683.001]
  • [Cites] Semin Respir Infect. 2000 Mar;15(1):41-51 [10749549.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):106-10 [11105051.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Am J Respir Crit Care Med. 2001 May;163(6):1304-9 [11371392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8774-9 [11438700.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):229-32 [9344234.001]
  • [Cites] Chest. 1998 Apr;113(4 Suppl):235S-241S [9552012.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):885-90 [9615736.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1739-50 [9802985.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17723-8 [16317067.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2105-12 [16288213.001]
  • [Cites] Mol Cancer Res. 2006 Apr;4(4):221-33 [16603636.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):1016-22 [16456147.001]
  • [Cites] Eur Respir J. 2006 Sep;28(3):523-32 [16611654.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):734-42 [17322026.001]
  • [Cites] Swiss Med Wkly. 2007 Jun 2;137(21-22):304-11 [17629808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1119-27 [18281487.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jun;38(6):629-38 [18096867.001]
  • [Cites] PLoS One. 2008;3(5):e2220 [18493606.001]
  • [Cites] Genesis. 2008 Jun;46(6):300-7 [18543320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193-9 [11700268.001]
  • (PMID = 18927348.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA105352
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Bacterial Proteins; 0 / Chemokines; 0 / NF-kappa B; 0 / Porins; 0 / Scgb1a1 protein, mouse; 0 / ompP2 protein, Haemophilus influenzae; 9060-09-7 / Uteroglobin; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2660561
  •  go-up   go-down


78. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


79. Xiao H, Hao X, Simi B, Ju J, Jiang H, Reddy BS, Yang CS: Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis; 2008 Jan;29(1):113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoid X receptor (RXR)alpha expression was reduced in high-grade dysplastic ACF, adenoma and adenocarcinoma during AOM-induced colon carcinogenesis, and the PPE treatment partially prevented the loss of RXRalpha expression in high-grade dysplastic ACF.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893236.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES005022
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


80. Ishiguro K, Yoshida T, Yagishita H, Numata Y, Okayasu T: Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut; 2006 May;55(5):695-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas.
  • BACKGROUND: Previously, we indicated that stromal genetic instability might contribute to tumorigenesis of both sporadic and ulcerative colitis associated colorectal adenocarcinomas.
  • Considering the established adenoma-adenocarcinoma sequence, in this study we analysed genetic instability in colorectal adenoma cells and surrounding stroma.
  • METHODS: In 164 colorectal tumours (34 hyperplastic polyps, 38 tubular adenomas with low grade dysplasia (TA-L), 51 tubular adenomas with high grade dysplasia (TA-H), and 41 invasive carcinomas), epithelial and stromal genetic instability with National Cancer Institute standard microsatellite markers and chromosome 17 (Chr17) markers, were analysed by a combination of laser capture microdissection and GeneScan approaches.
  • RESULTS: While frequencies of both loss of heterozygosity (LOH) and microsatellite instability (MSI) were extremely low in hyperplastic polyps, LOH in tubular adenomas was detected in both epithelial (TA-L 13.2%, TA-H 27.5%) and stromal (5.3% and 5.9%, respectively) elements, along with MSI (5.3% and 13.7%, and 5.3 and 5.9%, respectively).
  • On the other hand, frequencies of stromal LOH or MSI were almost constant (5.3% approximately 17.1%, 5.3% approximately 17.1%, respectively) in adenomas and invasive carcinomas.
  • Thus microenvironmental changes due to genetic alteration in Chr17 markers in stromal cells may play an important role in colon adenoma and adenocarcinoma development.
  • [MeSH-major] Adenoma / genetics. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 17. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Genomic Instability
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Chi-Square Distribution. Disease Progression. Epithelial Cells / metabolism. Female. Gene Frequency. Genes, p53. Genetic Markers. Humans. Immunohistochemistry / methods. Intestinal Mucosa / metabolism. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1994 Jun;7(2 Spec No):246-339 [7545953.001]
  • [Cites] Genomics. 1993 Sep;17(3):618-23 [8244378.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):40-5 [8978341.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):913-21 [9492020.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2562-6 [10811140.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1617-28 [11092522.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2236-8 [11956075.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2447-54 [11980631.001]
  • [Cites] J Pathol. 2003 Feb;199(2):166-75 [12533829.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):723-30 [12760292.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):707-12 [12915883.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6158-61 [14559796.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] Gastroenterology. 1974 Oct;67(4):636-45 [4414719.001]
  • [Cites] N Engl J Med. 1987 Jun 25;316(26):1654-8 [3295551.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):673-8 [3371139.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):75-9 [2296606.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • (PMID = 16354798.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1856111
  •  go-up   go-down


81. Hasumura M, Imai T, Takizawa T, Ueda M, Onose J, Hirose M: Promotion of thyroid carcinogenesis by para-aminobenzoic acid in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Toxicol Sci; 2005 Jul;86(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final incidence of thyroid follicular cell adenomas and adenocarcinomas was significantly (p < 0.05 or 0.01) increased in groups 3 and 4 as compared to group 1.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843508.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Thyroid Hormones; 53609-64-6 / diisopropanolnitrosamine; TL2TJE8QTX / 4-Aminobenzoic Acid
  •  go-up   go-down


82. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):163-71 [9196015.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):967-71 [11490850.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):900-5 [9041151.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):962-6 [11490849.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):35-41 [11148557.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1041-7 [10931048.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):826-33 [8039110.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):117-21 [12622422.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):277-83 [12579258.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW, Chung IS: [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2005 Jun;45(6):394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical expression of bcl-2, bcl-xL, bax, and p53 proteins according to the pathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in the gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal bcl-2, bcl-xL, bax, p53 antibodies were performed on paraffin embedded specimens from forty-one gastric adenomas and 100 gastric adenocarcinomas.
  • RESULTS: The expression rate of bcl-2 was higher in adenomas (34.2%), especially in high grade dysplasia (52.4%), than adenocarcinomas (2.0%).
  • The expression rate of bcl-xL was higher in adenocarcinomas (55.0%) than adenomas (22%).
  • The expression rate of the bax was higher in adenocarcinomas (58.0%) than adenomas (14.6%).
  • In the adenocarcinoma, the bax expression was significantly related with the depth of invasion, lymph node metastasis, and TNM stage.
  • The expression rate of p53 was higher in adenocarcinomas (64.0%) than adenomas (14.6%).
  • CONCLUSIONS: Bcl-2 protein would be related with the development of gastric adenoma, especially with high grade dysplasia.
  • Bcl-xL and p53 proteins would be involved in the development of relatively early stage of gastric adenocarcinoma but not in tumor progression.
  • Bax protein would be involved in the development of gastric adenocarcinoma and related with depth of invasion, lymph node metastasis, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973073.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


84. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


85. Fukuyama M, Rokutan K, Sano T, Miyake H, Shimada M, Tashiro S: Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. Cancer Lett; 2005 Apr 18;221(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon.
  • Adenomas and well differentiated adenocarcinomas up-regulated Nox1 expression.
  • Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Colonic Neoplasms / enzymology. NADPH Oxidase / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797632.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / NF-kappa B; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


86. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med; 2008 Sep 18;359(12):1207-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of CT colonography for detection of large adenomas and cancers.
  • The primary end point was detection by CT colonography of histologically confirmed large adenomas and adenocarcinomas (10 mm in diameter or larger) that had been detected by colonoscopy; detection of smaller colorectal lesions (6 to 9 mm in diameter) was also evaluated.
  • For large adenomas and cancers, the mean (+/-SE) per-patient estimates of the sensitivity, specificity, positive and negative predictive values, and area under the receiver-operating-characteristic curve for CT colonography were 0.90+/-0.03, 0.86+/-0.02, 0.23+/-0.02, 0.99+/-<0.01, and 0.89+/-0.02, respectively.
  • The per-polyp sensitivity for large adenomas or cancers was 0.84+/-0.04.
  • The per-patient sensitivity for detecting adenomas that were 6 mm or more in diameter was 0.78.
  • CONCLUSIONS: In this study of asymptomatic adults, CT colonographic screening identified 90% of subjects with adenomas or cancers measuring 10 mm or more in diameter.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] Radiology. 2005 Aug;236(2):519-26 [16040909.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):311-9 [12891530.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Br J Radiol. 2005 Jan;78(925):22-9 [15673525.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] J Periodontal Res. 1997 May;32(4):351-4 [9210088.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):517-21 [8623619.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):767-71 [15365402.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):631-8 [14975961.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):314-21 [15067626.001]
  • [CommentIn] Ann Intern Med. 2009 Feb 17;150(4):JC2-13 [19238611.001]
  • [CommentIn] Gastroenterology. 2009 Apr;136(4):1451-3 [19233331.001]
  • [CommentIn] N Engl J Med. 2008 Sep 18;359(12):1285-7 [18799563.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842-3; author reply 2843-4 [19115494.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2843; author reply 2843-4 [19115493.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842; author reply 2843-4 [19109581.001]
  • [ErratumIn] N Engl J Med. 2008 Dec 25;359(26):2853
  • (PMID = 18799557.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00084929
  • [Grant] United States / NCI NIH HHS / CA / CA080098-10; United States / NCI NIH HHS / CA / U01 CA080098; United States / NCI NIH HHS / CA / U01 CA080098-10
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS73206; NLM/ PMC2654614
  •  go-up   go-down


87. Park MJ, Kim DH, Lim SH, Yim JY, Kim YS, Cho KR, Kim CH, Jung HC, Song IS, Kim SS, Yoon DH, Shin CS, Cho SH, Oh BH, Lee DH: Features of Gastric Neoplasm Detected during the Screening Examination. Gut Liver; 2007 Jun;1(1):33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 25, 432 subjects, 122 cases of gastric neoplasms were detected including 61 adenocarcinoma (45 early gastric cancers), 53 adenoma, 7 mucosa-associated lymphoid tissue lymphoma, and one metastatic cancer.
  • There was no significant statistical difference in basal characteristics of the subjects between gastric adenocarcinoma and adenoma.
  • Metabolic syndrome was more prevalent in adenoma than in the control (p<0.05).
  • In addition, metabolic syndrome might be related with gastric adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1090-6 [9672336.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Ann Epidemiol. 1997 Oct;7(7):446-51 [9349911.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):839-43 [8633568.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Am J Surg. 1989 Jul;158(1):14-6 [2742043.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):69-74 [14985987.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jan;34(1):1-7 [15020656.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Annu Rev Public Health. 2003;24:413-33 [12428034.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):204-8 [12590229.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1276-85 [12360042.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):446-9 [11920598.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):811-8 [11857360.001]
  • [Cites] Gut. 2002 Mar;50(3):378-81 [11839718.001]
  • [Cites] Surgery. 2000 Jul;128(1):41-7 [10876184.001]
  • [Cites] J Gastroenterol. 1999;34 Suppl 11:91-6 [10616774.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Aug;18(8):821-9 [16825897.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):709-16 [16765306.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii103-8 [16760271.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):35-7 [9533759.001]
  • (PMID = 20485656.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871660
  • [Keywords] NOTNLM ; Adenoma / Gastric cancer / Helicobacter pylori / Risk factor / Screening / Stomach
  •  go-up   go-down


88. Scherübl H, Klöppel G: [Rectal carcinoids on the rise - update]. Z Gastroenterol; 2009 Apr;47(4):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to the early detection of colorectal adenoma and adenocarcinoma, screening colonoscopy also makes possible the early detection and early therapy for neuroendocrine rectal tumours/carcinomas.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358064.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


89. Habermann N, Schön A, Lund EK, Glei M: Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. Apoptosis; 2010 May;15(5):621-30